Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

9 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04979650 (ClinicalTrials.gov)	May 22, 2021	2/7/2021	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis	Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023	Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;Methylprednisolone	Drug: Methylprednisolone succinate;Drug: Normal saline	Mazandaran University of Medical Sciences	NULL	Enrolling by invitation	18 Years	55 Years	All	104	Phase 2	Iran, Islamic Republic of
2	NCT01973517 (ClinicalTrials.gov)	April 2014	16/10/2013	High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	Multiple Sclerosis	Drug: Feraheme;Drug: Gadolinium -based contrast	Stanford University	NULL	Withdrawn	18 Years	N/A	All	0		United States
3	NCT01767701 (ClinicalTrials.gov)	April 2013	7/1/2013	Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis	A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI	Relapsing Remitting Multiple Sclerosis	Drug: Raltegravir	Queen Mary University of London	Merck Sharp & Dohme Corp.	Completed	18 Years	55 Years	All	23	Phase 2	United Kingdom
4	EUCTR2012-004847-61-GB (EUCTR)	16/01/2013	18/12/2012	INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS	A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS)	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: ISENTRESS Product Name: raltegravir INN or Proposed INN: lactose monohydrate	Queen Mary University of London	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom
5	NCT01567553 (ClinicalTrials.gov)	April 2009	24/2/2012	The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.	Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.	Multiple Sclerosis (MS);Inflammatory Disease	Other: USPIO MRI - Gadolinium MRI	Rennes University Hospital	Bayer;Bayer	Terminated	18 Years	45 Years	Both	37	N/A	France
6	EUCTR2006-004736-79-CZ (EUCTR)	06/03/2007	17/10/2006	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.	Product Name: ATL1102 Product Code: ATL1102	Antisense Therapeutics Ltd.	NULL	Not Recruiting			Female: yes Male: yes	80		Czech Republic
7	EUCTR2006-004736-79-SK (EUCTR)	19/01/2007	17/10/2006	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.	Product Name: ATL1102 Product Code: ATL1102	Antisense Therapeutics Ltd.	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	Czech Republic;Slovakia
8	NCT00176592 (ClinicalTrials.gov)	January 2003	13/9/2005	Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI	Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium	Multiple Sclerosis	Drug: Betaseron;Drug: Copaxone	Stuart D Cook MD	NULL	Active, not recruiting	18 Years	55 Years	Both	93	Phase 4	United States
9	NCT00006060 (ClinicalTrials.gov)	April 1999	5/7/2000	Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: standard gadolinium contrast	National Center for Research Resources (NCRR)	University of Pennsylvania	Recruiting	20 Years	70 Years	Both	100	N/A	United States